- Home
- CBIO vs CURV Comparison
CBIO vs CURV Comparison
Compare CBIO & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- CURV
- Stock Information
- Founded
- CBIO 2003
- CURV 2001
- Country
- CBIO United States
- CURV United States
- Employees
- CBIO N/A
- CURV N/A
- Industry
- CBIO
- CURV Clothing/Shoe/Accessory Stores
- Sector
- CBIO
- CURV Consumer Discretionary
- Exchange
- CBIO Nasdaq
- CURV Nasdaq
- Market Cap
- CBIO 308.0M
- CURV 215.9M
- IPO Year
- CBIO N/A
- CURV 2021
- Fundamental
- Price
- CBIO $14.29
- CURV $2.16
- Analyst Decision
- CBIO Strong Buy
- CURV Hold
- Analyst Count
- CBIO 5
- CURV 4
- Target Price
- CBIO $25.60
- CURV $4.00
- AVG Volume (30 Days)
- CBIO 98.3K
- CURV 482.6K
- Earning Date
- CBIO 07-31-2025
- CURV 09-04-2025
- Dividend Yield
- CBIO N/A
- CURV N/A
- EPS Growth
- CBIO N/A
- CURV N/A
- EPS
- CBIO N/A
- CURV 0.09
- Revenue
- CBIO N/A
- CURV $1,089,931,000.00
- Revenue This Year
- CBIO N/A
- CURV N/A
- Revenue Next Year
- CBIO N/A
- CURV N/A
- P/E Ratio
- CBIO N/A
- CURV $24.08
- Revenue Growth
- CBIO N/A
- CURV N/A
- 52 Week Low
- CBIO $10.83
- CURV $2.08
- 52 Week High
- CBIO $21.40
- CURV $7.25
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- CURV 35.39
- Support Level
- CBIO $13.50
- CURV $2.13
- Resistance Level
- CBIO $16.00
- CURV $2.24
- Average True Range (ATR)
- CBIO 0.79
- CURV 0.10
- MACD
- CBIO 0.16
- CURV 0.05
- Stochastic Oscillator
- CBIO 39.68
- CURV 38.30
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.